Companies / BOC Sciences / Sintilimab
BOC Sciences

Sintilimab | BOC Sciences

Sintilimab is a human monoclonal antibody that targets PD-1 and blocks the interaction with its ligands. Sintilimab has been approved for the treatment of Hodgkin's lymphoma.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.